Svs7 Inhibitors
The Svs7 Inhibitors chemical class comprises a diverse set of compounds targeting various aspects of lysosomal function and related cellular processes crucial for Svs7 activity. Bafilomycin A1 and Concanamycin A inhibit Svs7 by disrupting lysosomal acidification through V-ATPase inhibition. Chloroquine raises lysosomal pH, impairing Svs7 function indirectly. Leupeptin, Pepstatin A, and E-64 interfere with lysosomal protease activity, preventing Svs7 degradation. Monensin disrupts ion gradients in lysosomal membranes, impacting Svs7 activity. Resveratrol modulates autophagy, indirectly influencing Svs7. Rapamycin inhibits Svs7 through mTOR inhibition, and Ebselen acts as a redox modulator, affecting lysosomal function. Niclosamide modulates AMPK, and Nilotinib targets c-Abl kinase, both indirectly influencing Svs7 activity. This diverse class collectively interferes with multiple cellular processes linked to lysosomal function and Svs7 activity, providing potential strategies for modulation in cellular contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 inhibits Svs7 by targeting vacuolar-type H+-ATPase (V-ATPase), disrupting lysosomal acidification. Svs7, localized in lysosomes, is affected by impaired lysosomal function, leading to inhibition. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $65.00 $162.00 $650.00 $2550.00 | 109 | |
Concanamycin A inhibits Svs7 through V-ATPase inhibition, similar to Bafilomycin A1. By disrupting lysosomal acidification, it hampers the activity of Svs7, which relies on proper lysosomal function for its optimal function. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine inhibits Svs7 indirectly by raising lysosomal pH, affecting V-ATPase activity. This disruption of lysosomal function impairs Svs7 function, which relies on an acidic lysosomal environment for proper activation. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $72.00 $145.00 $265.00 $489.00 $1399.00 $99.00 | 19 | |
Leupeptin inhibits Svs7 by interfering with lysosomal protease activity. Svs7 is a substrate for lysosomal degradation, and leupeptin prevents its degradation, leading to an inhibition of Svs7 activity. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $275.00 $928.00 $1543.00 | 14 | |
E-64 inhibits Svs7 by targeting lysosomal cysteine proteases. Svs7, being a substrate for lysosomal degradation, is protected from degradation when cysteine protease activity is blocked, resulting in the inhibition of Svs7. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin inhibits Svs7 through disruption of ion gradients across lysosomal membranes. This interference affects lysosomal function, hindering Svs7 activity, which is dependent on the proper ionic environment within lysosomes. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol inhibits Svs7 by modulating autophagy. It indirectly influences Svs7 activity by regulating cellular processes that impact lysosomal function, leading to the inhibition of Svs7. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits Svs7 through mTOR inhibition. Svs7 is indirectly influenced by disrupting mTOR signaling, as it plays a role in the regulation of autophagy, a process linked to Svs7 activity and lysosomal function. | ||||||
Ebselen | 60940-34-3 | sc-200740B sc-200740 sc-200740A | 1 mg 25 mg 100 mg | $32.00 $133.00 $449.00 | 5 | |
Ebselen inhibits Svs7 by acting as a redox modulator. Its impact on cellular redox balance can disrupt lysosomal function and affect Svs7 activity, making it an indirect inhibitor of Svs7 through modulation of cellular processes. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $37.00 $77.00 $184.00 $510.00 $1224.00 $5814.00 | 8 | |
Niclosamide inhibits Svs7 through modulation of AMPK activity. AMPK is involved in cellular energy regulation and autophagy, processes linked to Svs7 function. Niclosamide's impact on AMPK indirectly influences Svs7 activity. | ||||||